

# Lianne S Gensler

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/629073/publications.pdf>

Version: 2024-02-01

61  
papers

3,917  
citations

236833

25  
h-index

143943

57  
g-index

63  
all docs

63  
docs citations

63  
times ranked

4387  
citing authors

#	ARTICLE	IF	CITATIONS
1	Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 3-17.	0.5	484
2	2019 Update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis. <i>Arthritis and Rheumatology</i> , 2019, 71, 1599-1613.	2.9	401
3	The Impact of Tumor Necrosis Factor Inhibitors on Radiographic Progression in Ankylosing Spondylitis. <i>Arthritis and Rheumatism</i> , 2013, 65, 2645-2654.	6.7	391
4	American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network 2015 Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis. <i>Arthritis and Rheumatology</i> , 2016, 68, 282-298.	2.9	383
5	Effect of Immunosuppression on the Immunogenicity of mRNA Vaccines to SARS-CoV-2. <i>Annals of Internal Medicine</i> , 2021, 174, 1572-1585.	2.0	273
6	Major histocompatibility complex associations of ankylosing spondylitis are complex and involve further epistasis with ERAP1. <i>Nature Communications</i> , 2015, 6, 7146.	5.8	220
7	Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active ankylosing spondylitis (TORTUGA): results from a randomised, placebo-controlled, phase 2 trial. <i>Lancet</i> , 2018, 392, 2378-2387.	6.3	198
8	Tofacitinib for the treatment of ankylosing spondylitis: a phase III, randomised, double-blind, placebo-controlled study. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1004-1013.	0.5	124
9	Genetic Dissection of Acute Anterior Uveitis Reveals Similarities and Differences in Associations Observed With Ankylosing Spondylitis. <i>Arthritis and Rheumatology</i> , 2015, 67, 140-151.	2.9	114
10	Ustekinumab Safety in Psoriasis, Psoriatic Arthritis, and Crohn's Disease: An Integrated Analysis of Phase II/III Clinical Development Programs. <i>Drug Safety</i> , 2019, 42, 751-768.	1.4	93
11	Measurement properties of the ASAS Health Index: results of a global study in patients with axial and peripheral spondyloarthritis. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 1311-1317.	0.5	85
12	The Concept of Axial Spondyloarthritis: Joint Statement of the Spondyloarthritis Research and Treatment Network and the Assessment of SpondyloArthritis International Society in Response to the US Food and Drug Administration's Comments and Concerns. <i>Arthritis and Rheumatology</i> , 2014, 66, 2649-2656.	2.9	81
13	Efficacy and safety of ixekizumab through 52 weeks in two phase 3, randomised, controlled clinical trials in patients with active radiographic axial spondyloarthritis (COAST-V and COAST-W). <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 176-185.	0.5	76
14	Cardiovascular morbidity and mortality in ankylosing spondylitis and psoriatic arthritis. <i>Best Practice and Research in Clinical Rheumatology</i> , 2018, 32, 369-389.	1.4	73
15	A Fifty-Week, Randomized, Placebo-Controlled Trial of Certolizumab Pegol in Nonradiographic Axial Spondyloarthritis. <i>Arthritis and Rheumatology</i> , 2019, 71, 1101-1111.	2.9	71
16	Association study of genes related to bone formation and resorption and the extent of radiographic change in ankylosing spondylitis. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1387-1393.	0.5	69
17	American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network 2015 Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis. <i>Arthritis Care and Research</i> , 2016, 68, 151-166.	1.5	53
18	Maintenance of clinical remission in early axial spondyloarthritis following certolizumab pegol dose reduction. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 920-928.	0.5	53

#	ARTICLE	IF	CITATIONS
19	HLA class I and II alleles in susceptibility to ankylosing spondylitis. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 66-73.	0.5	52
20	Polygenic Risk Scores have high diagnostic capacity in ankylosing spondylitis. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1168-1174.	0.5	49
21	MICA, a gene contributing strong susceptibility to ankylosing spondylitis. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1552-1557.	0.5	47
22	Updates in adult-onset Still disease: Atypical cutaneous manifestations and associations with delayed malignancy. <i>Journal of the American Academy of Dermatology</i> , 2015, 73, 294-303.	0.6	43
23	National Lupus Hospitalization Trends Reveal Rising Rates of Herpes Zoster and Declines in Pneumocystis Pneumonia. <i>PLoS ONE</i> , 2016, 11, e0144918.	1.1	37
24	Biologic therapy and spinal radiographic progression in patients with axial spondyloarthritis: A structured literature review. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2020, 12, 1759720X2090604.	1.2	34
25	Axial Involvement in Psoriatic Arthritis cohort (AXIS): the protocol of a joint project of the Assessment of SpondyloArthritis international Society (ASAS) and the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA). <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2021, 13, 1759720X2110579.	1.2	30
26	Axial spondyloarthritis: the heart of the matter. <i>Clinical Rheumatology</i> , 2015, 34, 995-998.	1.0	23
27	Spontaneous, drug-induced, and drug-free remission in peripheral and axial spondyloarthritis. <i>Best Practice and Research in Clinical Rheumatology</i> , 2014, 28, 807-818.	1.4	22
28	Opioid Analgesic Use in Patients with Ankylosing Spondylitis: An Analysis of the Prospective Study of Outcomes in an Ankylosing Spondylitis Cohort. <i>Journal of Rheumatology</i> , 2018, 45, 188-194.	1.0	20
29	Association of body mass index on disease activity in axial spondyloarthritis: systematic review and meta-analysis. <i>RMD Open</i> , 2020, 6, e001225.	1.8	20
30	Nonradiographic axial spondyloarthritis. <i>Best Practice and Research in Clinical Rheumatology</i> , 2017, 31, 816-829.	1.4	19
31	Continuing versus withdrawing ixekizumab treatment in patients with axial spondyloarthritis who achieved remission: efficacy and safety results from a placebo-controlled, randomised withdrawal study (COAST-Y). <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1022-1030.	0.5	18
32	Endpoints for extraintestinal manifestations in inflammatory bowel disease trials: the EXTRA consensus from the International Organization for the Study of Inflammatory Bowel Diseases. <i>The Lancet Gastroenterology and Hepatology</i> , 2022, 7, 254-261.	3.7	18
33	Secukinumab in non-radiographic axial spondyloarthritis: subgroup analysis based on key baseline characteristics from a randomized phase III study, PREVENT. <i>Arthritis Research and Therapy</i> , 2021, 23, 231.	1.6	17
34	Achievement of Remission Endpoints with Secukinumab Over 3 Years in Active Ankylosing Spondylitis: Pooled Analysis of Two Phase 3 Studies. <i>Rheumatology and Therapy</i> , 2021, 8, 273-288.	1.1	11
35	Combined Single Cell Transcriptome and Surface Epitope Profiling Identifies Potential Biomarkers of Psoriatic Arthritis and Facilitates Diagnosis via Machine Learning. <i>Frontiers in Immunology</i> , 2022, 13, 835760.	2.2	11
36	Successful treatment of mucous membrane pemphigoid with bortezomib. <i>JAAD Case Reports</i> , 2018, 4, 81-83.	0.4	10

#	ARTICLE	IF	CITATIONS
37	Safety and Efficacy of Bimekizumab in Patients With Active Ankylosing Spondylitis: 3-Year Results From a Phase IIb Randomized Controlled Trial and Its Open-Label Extension Study. <i>Arthritis and Rheumatology</i> , 2022, 74, 1943-1958.	2.9	9
38	Longitudinal associations between depressive symptoms and clinical factors in ankylosing spondylitis patients: analysis from an observational cohort. <i>Rheumatology International</i> , 2020, 40, 1053-1061.	1.5	8
39	Identifying trajectories of radiographic spinal disease in ankylosing spondylitis: a 15-year follow-up study of the PSOAS cohort. <i>Rheumatology</i> , 2022, 61, 2079-2087.	0.9	8
40	Effects of secukinumab on bone mineral density and bone turnover biomarkers in patients with ankylosing spondylitis: 2-year data from a phase 3 study, MEASURE 1. <i>BMC Musculoskeletal Disorders</i> , 2021, 22, 1037.	0.8	8
41	Impact of HLA-B27 and Disease Status on the Gut Microbiome of the Offspring of Ankylosing Spondylitis Patients. <i>Children</i> , 2022, 9, 569.	0.6	8
42	MR distribution of active inflammatory and chronic structural sacroiliac joint changes in axial spondyloarthritis: Challenging conventional wisdom. <i>Clinical Imaging</i> , 2019, 58, 70-73.	0.8	7
43	Ixekizumab Improves Functioning and Health in the Treatment of Radiographic Axial Spondyloarthritis: Week 52 Results from 2 Pivotal Studies. <i>Journal of Rheumatology</i> , 2021, 48, 188-197.	1.0	7
44	Relationship Between Body Mass Index, Disease Activity, and Exercise in Ankylosing Spondylitis. <i>Arthritis Care and Research</i> , 2022, 74, 1287-1293.	1.5	7
45	Physical activity in axial spondyloarthritis—tails from bench to bedside. <i>Clinical Rheumatology</i> , 2016, 35, 1443-1445.	1.0	5
46	Cardiovascular Risk Scores in Axial Spondyloarthritis Versus the General Population: A Cross-sectional Study. <i>Journal of Rheumatology</i> , 2021, 48, 361-366.	1.0	5
47	Reactogenicity of the Messenger RNA SARS-CoV-2 Vaccines Associated With Immunogenicity in Patients With Autoimmune and Inflammatory Disease. <i>Arthritis Care and Research</i> , 2022, 74, 1953-1960.	1.5	5
48	Ixekizumab in radiographic axial spondyloarthritis with and without elevated C-reactive protein or positive magnetic resonance imaging. <i>Rheumatology</i> , 2022, 61, 4324-4334.	0.9	4
49	The changing profile of ankylosing spondylitis in the biologic era. <i>Clinical Rheumatology</i> , 2020, 39, 2641-2651.	1.0	3
50	Chronic back pain in first-degree relatives (FDRs) of patients with ankylosing spondylitis: predictive value of HLA-B27 and persistence of inflammatory back pain over time. <i>RMD Open</i> , 2020, 6, e001418.	1.8	3
51	The Association of Tumor Necrosis Factor Inhibitor Use With Incident Hypertension in Ankylosing Spondylitis: Data From the PSOAS Cohort. <i>Journal of Rheumatology</i> , 2021, , jrheum.210332.	1.0	3
52	Does psoriatic axial spondyloarthritis phenotype correlate with imaging morphotype?. <i>Clinical and Experimental Rheumatology</i> , 2020, 38, 329-332.	0.4	3
53	A Terminal Event. <i>New England Journal of Medicine</i> , 2019, 381, 970-976.	13.9	2
54	A latent class based imputation method under Bayesian quantile regression framework using asymmetric Laplace distribution for longitudinal medication usage data with intermittent missing values. <i>Journal of Biopharmaceutical Statistics</i> , 2020, 30, 160-177.	0.4	2

#	ARTICLE	IF	CITATIONS
55	Do geography and ethnicity play a role in juvenile Spondyloarthritis? A multi-center binational retrospective study. <i>Pediatric Rheumatology</i> , 2021, 19, 4.	0.9	2
56	Long-term safety and clinical outcomes of certolizumab pegol treatment in patients with active non-radiographic axial spondyloarthritis: 3-year results from the phase 3 C-axSpAnd study. <i>RMD Open</i> , 2022, 8, e002138.	1.8	2
57	COVID-19 Outcomes and Vaccination in Patients with Spondyloarthritis. <i>Rheumatology and Therapy</i> , 0, , .	1.1	1
58	Virtually Speaking: The Impact of a Nationwide Synchronous and Asynchronous Learning Forum. <i>Arthritis Care and Research</i> , 2023, 75, 1563-1570.	1.5	1
59	Minimal Impact of the COVID-19 Pandemic on Disease Activity and Health-Related Quality of Life in Patients With Ankylosing Spondylitis Receiving Bimekizumab: Exploratory Analyses From a Phase 2b Open-Label Extension Study. <i>ACR Open Rheumatology</i> , 0, , .	0.9	1
60	Efficacy and safety outcomes in patients with axial spondyloarthritis treated with certolizumab pegol: results from the 48-week run-in part of a 96-week study (NCT02505542). <i>Rheumatology</i> , 2019, 58, .	0.9	0
61	Certolizumab Pegol Efficacy in Patients With Non-Radiographic Axial Spondyloarthritis Stratified by Baseline MRI and C-Reactive Protein Status: An Analysis From the C-axSpAnd Study. <i>ACR Open Rheumatology</i> , 0, , .	0.9	0